Meeting
2023 ASCO Annual Meeting
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
Authors
Bradley Corr
University of Colorado Cancer Center, Aurora, CO
Bradley Corr , Ashley Ford Haggerty , Sarah E. Taylor , Stefan Gysler , Mark Aloysuis Morgan , Kian Behbakht , Carolyn Lefkowits , Jill Alldredge , Lindsay Brubaker , Samantha Hopp , Saketh R Guntupalli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT03617679
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5626)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5626
Abstract #
TPS5626
Poster Bd #
314a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.
First Author: Helen Mackay
Poster
2023 ASCO Annual Meeting
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.
First Author: Kim Anna Reiss
First Author: B.J. Rimel
Poster
2021 ASCO Annual Meeting
PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.
First Author: Fortunato Ciardiello